BioLineRX Ltd. is an Israel-based company engaged in identifying and following the critical pathway to commercialization of therapeutic compounds. Led by Dr. Kinneret Savitsky, the Company's pre-clinical drug development program is referred to as BioLine Innovations Jerusalem (BIJ), supported by the Israeli Office of the Chief Scientist's national biotechnology initiative. BIJ is positioned to take early stage compounds through rigorous pre-clinical tests on their way to clinical trials. It builds its pipeline by in-licensing compounds from scientists, universities and biotech companies and advances these projects through the clinical testing stage. The Company implements its development plan using certified clinical research organizations and regulatory agency compliant materials and testing.